Pancragen (KEDW)

KEDW Tetrapeptide | Pancreas Bioregulator

Weight: 576 Da
Half-life: Not established
Chain: 4 amino acids
4 studies
2017 latest
Moderate Research
Dose 10-20mg daily
Frequency Daily for 10-20 days per cycle
Cycle 10-20 days
Storage Capsules at room temperature; reconstituted injectable at 2-8°C refrigerated

Community Research

Join others researching Pancragen — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances.

Mechanism of Action

Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures to modulate pancreatic gene expression. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Its small size (4 amino acids, ~576 Da) allows it to traverse cellular membranes and interact with nuclear components including histones and DNA.

01 Corrects impaired glucose tolerance
02 Normalizes insulin levels
03 Normalizes C-peptide levels
04 Improves endocrine pancreatic function
05 Supports pancreatic cell differentiation
06 Regulates melatonin expression
07 Reduces metabolic syndrome incidence
08 Upregulates key pancreatic transcription factors

Molecular Data

Molecular Weight
576 Da
Chain Length
4 amino acids
Type
Tetrapeptide bioregulator
Amino Acid Sequence
One-letter: KEDW
H₂N
K 1
O ‖ C
N
E 2
O ‖ C
N
D 3
O ‖ C
N
W 4
COOH
Lys
1

Lysine

Position 1

Glu
2

Glutamic Acid

Position 2

Asp
3

Aspartic Acid

Position 3

Trp
4

Tryptophan

Position 4

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Research Indications

Metabolic Support
Impaired Glucose Tolerance effective

Corrects age-related glucose tolerance disturbances in primate studies.

Metabolic Syndrome moderate

Reduces incidence and magnitude of metabolic syndrome.

Blood Sugar Regulation moderate

Helps control blood sugar through pancreatic function support.

Pancreatic Health
Pancreatic Cell Differentiation effective

Impacts differentiation of pancreatic cells during aging.

Endocrine Function effective

Improves endocrine function of the pancreas.

Age-Related Pancreatic Decline moderate

Addresses age-related imbalance of pancreatic function.

Anti-Aging
Gene Expression Regulation moderate

Directly interacts with DNA to regulate pancreatic gene expression.

Dosing Protocols

Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles.

GoalDoseFrequencyRoute
Standard protocol10-20 mgDaily for 10-20 daysOral capsules
Maintenance10 mg2-3 cycles yearlyOral capsules

Interactions

++
Epitalon
Often combined in comprehensive anti-aging Khavinson protocols.
synergistic
+
Livagen
Different organ targets; can be used in comprehensive bioregulator protocols.
compatible
+
Vilon
Part of Khavinson bioregulator family; targets different tissue.
compatible
?
GLP-1 agonists
Both affect glucose metabolism; interaction unknown.
unknown

What to Expect

During cycle
Gene expression modulation begins
Post-cycle
Effects persist due to epigenetic changes
Weeks-Months
Glucose tolerance and pancreatic function improvements
Long-term
Cumulative benefits with periodic cycles

Side Effects & Safety

Common Side Effects

  • Generally well-tolerated
  • Minimal side effects reported

Stop Signs - Discontinue if:

  • Allergic reactions
  • Unusual blood sugar changes
  • Signs of hypoglycemia

Contraindications

  • Active pancreatic emergencies (seek medical care)
  • Known hypersensitivity
  • Pregnancy or breastfeeding
  • Type 1 diabetes (consult physician)

Quality Checklist

Good Signs

  • White powder or capsules
  • Clear solution if reconstituted
  • Proper packaging and labeling

Warning Signs

  • Unknown source or purity

Bad Signs

  • Discoloration
  • Unusual odor
  • Damaged packaging

References

  • Correction of Impaired Glucose Tolerance Using Tetrapeptide (Pancragen) in Old Female Rhesus Monkeys
    PubMed (2017)

    Pancragen normalized insulin and C-peptide levels, suggesting recovery of disturbed glucose tolerance in old animals.

  • Tetrapeptide KEDW Interacts with DNA and Regulates Gene Expression
    Bulletin of Experimental Biology and Medicine (2015)

    KEDW directly interacts with DNA and regulates pancreatic gene expression.

  • Impacts of Pancragen on Differentiation of Pancreatic Cells During Aging
    Bulletin of Experimental Biology and Medicine (2013)

    Pancragen affects pancreatic cell differentiation during aging process.

  • Prospects of Using Pancragen for Metabolic Disorders in Elderly
    Bulletin of Experimental Biology and Medicine (2011)

    Pancragen shows promise for correction of metabolic disorders in elderly people.

Related Peptides

Epitalon synergistic

Often combined in comprehensive anti-aging Khavinson protocols.

Livagen compatible

Different organ targets; can be used in comprehensive bioregulator protocols.

Vilon compatible

Part of Khavinson bioregulator family; targets different tissue.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.